Crysvita Európska únia - slovenčina - EMA (European Medicines Agency)

crysvita

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - lieky na liečbu chorôb kostí - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Furosemid FMK 40 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

furosemid fmk 40 mg

farmak international sp. z o.o., poľsko - furosemid - 50 - diuretica

Furosemid Medreg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

furosemid medreg

medreg s.r.o., Česká republika - furosemid - 50 - diuretica

Furosemid Kabi 20 mg/2 ml Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

furosemid kabi 20 mg/2 ml

fresenius kabi s.r.o., Česká republika - furosemid - 50 - diuretica